20 December 2024 - In head to head clinical trials, Alyftrek was non-inferior on ppFEV1 and further decreased sweat chloride compared to Trikafta.

Vertex Pharmaceuticals today announced that the US FDA has approved Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), a once daily next in class triple combination cystic fibrosis transmembrane conductance regulator modulator for the treatment of cystic fibrosis in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to Alyftrek.

Read Vertex Pharmaceuticals press release